QuidelOrtho Corporation
27.94-0.25 (-0.89%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · QDEL · USD
Key Stats
Market Cap
1.90BP/E (TTM)
-Basic EPS (TTM)
-6.84Dividend Yield
0%Recent Filings
8-K
QuidelOrtho completes debt refinancing with extended maturities and reduced amortization.
QuidelOrtho Corporation announces the completion of a debt refinancing transaction on August 21, 2025, extending maturities and reducing amortization payments. The new structure includes a $1.15 billion 5-year senior secured Term Loan A replacing the previous Term Loan A, a $100 million undrawn delayed draw Term Loan A, a $1.45 billion 7-year senior secured Term Loan B, and a $700 million revolving credit facility replacing the prior credit facility. This refinancing strengthens the capital structure and provides greater financial flexibility for growth while prioritizing debt reduction.
10-Q
Q2 FY2025 results
QuidelOrtho posted Q2 revenues of $613.9 million, down 4% year-over-year yet edging up 7% from Q1's $692.8 million (derived), as Labs and Immunohematology grew 4% annually on reagent strength, while Point of Care dipped 21% from fading COVID sales and Donor Screening plunged 61% amid U.S. wind-down. Gross margin improved to 44.8% from 43.3% a year ago, fueled by procurement savings, but operating loss widened to $180.7 million versus $117.5 million, driven by $178.9 million in restructuring and Savanna exit charges; net loss hit $255.4 million, or $3.77 per diluted share on 67.7 million shares, with anti-dilution excluding 0.2 million potential shares. Cash climbed to $151.7 million, bolstered by $18.8 million operating cash flow, while total debt stood at $2,606.3 million with $397.3 million revolver availability and covenant compliance. The Optimization Plan eyes $50 million in net savings by 2027. Ongoing securities litigation poses disclosure risks.
8-K
Q2 revenue dips, margins rise
QuidelOrtho reported Q2 2025 revenue of $614 million, down 3.6% year-over-year due to lower COVID-19 and donor screening sales, yet labs revenue grew 4% as reported. Adjusted EBITDA margin expanded 330 basis points to 17%, fueled by $100 million in annualized cost savings from 2024 initiatives, including Savanna platform discontinuation and manufacturing consolidation. The company announced intent to acquire LEX Diagnostics. Full-year 2025 guidance remains unchanged. Cost savings drive profitability amid revenue headwinds.
8-K
Stockholders approve equity plan expansion
QuidelOrtho stockholders approved the Second Amended and Restated 2018 Equity Incentive Plan at the May 20, 2025 annual meeting, adding 6,200,000 shares to the pool and extending the term to 2035. All eleven director nominees were elected, executive pay was ratified on an advisory basis, and KPMG's auditor role was confirmed. This bolsters talent retention amid diagnostics competition. Pool now totals 9,350,000 shares.
10-Q
Q1 FY2025 results
QuidelOrtho posted Q1 FY2025 revenues of $692.8M, down 3% y/y from $711.0M, with Labs up 5% to $373.1M on reagent growth yet Point of Care off 8% from lower COVID-19 sales and Donor Screening plunging 62% amid U.S. portfolio wind-down; gross margin expanded to 49.6% from 46.7% via procurement savings. Operating income swung to $32.6M from a $1,758.0M loss, excluding last year's $1,743.9M goodwill impairment, while net loss narrowed to $12.7M or $(0.19) diluted EPS on 67.5M shares—anti-dilution excluded 0.4M potential shares. Cash from operations hit $65.6M, funding $56.2M capex for a derived $9.4M free cash flow, with $127.1M cash and $537.3M revolver availability against $2,499.7M debt under compliant covenants. Integration costs eased to $16.1M. Ongoing securities litigation poses disclosure risks.
ABT
Abbott Laboratories
124.43-2.18
BIO
Bio-Rad Laboratories, Inc.
319.47-10.95
BRKR
Bruker Corporation
37.74-0.98
CODX
Co-Diagnostics, Inc.
0.49-0.08
DGX
Quest Diagnostics Incorporated
174.78-3.50
MASI
Masimo Corporation
142.91-3.50
QTRX
Quanterix Corporation
5.17-0.31
RVTY
Revvity, Inc.
95.30-1.15
SMLR
Semler Scientific, Inc.
25.99-1.23
ZOMDF
Zomedica Corp.
0.07+0.00